Delivery of large payloads
The disclosure includes non-naturally occurring or engineered CRISPR systems and proteins, associated with a delivery system comprising a virus component and a lipid component. The disclosure includes CRISPR proteins associated with capsid proteins, e.g., AAV VP1VP2, and/or VP3, on the surface of or internal to the AAV, along with compositions, systems and complexes involving the AAV-CRISPR protein, nucleic acid molecules and vectors encoding the same, deliver}-systems, and uses therefor.
1. A particle delivery system comprising a composite virus particle,
wherein the composite virus particle comprises a lipid, at least a portion of a virus capsid protein, and at least a portion of a non-capsid protein or peptide, wherein the composite virus particle is adsorbed to a liposome comprising a targeting moiety,
wherein the lipid is selected from EC16-63; 80-O14B; 80-O16B; 80-O18B; 87-O14B; 87-O16B; 87-O18B; 1-O18B: 80-O14; 80-O16; 80-O18; 87-O14; 87-O16; 87-O18; 1N16; 1-N18; 87-N17; 87-N16; 87-N18; EC 16-1; EC 16-3; EC16-12; EC16-14; and mixtures thereof.
2. The particle delivery system of claim 1 , wherein the composite virus particle is adsorbed to a liposome by a hydrophobic interaction or an electrostatic interaction.
3. The particle delivery system of claim 2 , wherein the liposome comprises:
a CRISPR system component; or
a CRISPR system component attached to the virus capsid protein.
4. A delivery system comprising one or more hybrid virus capsid proteins in combination with a lipid particle, wherein the one or more hybrid virus capsid proteins comprise at least a portion of a virus capsid protein attached to at least a portion of a non-capsid protein, wherein a virus particle is adsorbed to a liposome comprising a targeting moiety,
wherein the lipid particle is selected from: EC16-63; 80-O14B; 80-O16B; 80-O18B; 87-O14B; 87-O16B; 87-O18B; 1-O18B; 80-O14; 80-O16; 80-O18; 87-O14; 87-O16; 87-O18; 1-N16; 1-N18; 87-N17; 87-N16; 87-N18; EC16-1; EC16-3; EC-16-12; EC16-14; and mixtures thereof.
5. The delivery system of claim 4 , wherein the portion of a virus capsid protein is attached to a surface of the lipid particle.
6. The delivery system of claim 5 , wherein the portion of the virus capsid protein is attached to the surface of the lipid particle by an electrostatic interaction or a hydrophobic interaction.
7. A delivery system comprising a particle comprising a lipid layer, wherein a hybrid virus capsid protein comprising at least a portion of a virus capsid protein attached to a least a portion of a non-capsid protein is embedded in the lipid layer, wherein the virus capsid protein is adsorbed to a liposome comprising a targeting moiety,
wherein the lipid particle is selected from: EC16-63; 80-O14B; 80-O16B; 80-O18B; 87-O14B; 87-O16B; 87-O18B; 1-O18B; 80-O14; 80-O16; 80-O18; 87-O14; 87-O16; 87-O18; 1-N16; 1-N18; 87-N17; 87-N16; 87-N18; EC16-1; EC16-3; EC-16-12; EC16-14; and mixtures thereof.
8. The delivery system of claim 7 , wherein the particle has a diameter of between 100 and 1000 nm.
9. The particle delivery system of claim 1 wherein the non-capsid protein or peptide:
has a molecular weight of up to a megadalton;
has a molecular weight in a range of 110 to 160 kDA;
comprises a CRISPR protein or peptide, or
comprises Cas9, a Cpf1 or a Cas13a.
10. The particle delivery system of claim 1 further comprising a wild-type capsid protein.
11. The particle delivery system of claim 10 , wherein a weight ratio of hybrid capsid protein to wild-type capsid protein is from 1:10 to 1:1.
12. The particle delivery system of claim 1 , wherein the virus capsid protein comprises an Adenoviridae or a Parvoviridae or a Rhabdoviridae or an enveloped virus having a glycoprotein protein;
an adeno-associated virus (AAV) or an adenovirus or a VSV or a rabies virus;
a retrovirus;
a lentivirus; or
murine leukemia virus (MuMLV).
13. The particle delivery system of claim 1 , wherein the virus capsid protein comprises VP1, VP2 or VP3.
14. The particle delivery system of claim 13 wherein the virus capsid protein is VP3, and the non-capsid protein is inserted into, tethered, or connected to VP3 loop 3 or loop 6.
15. The particle delivery system of claim 1 , wherein the particle delivery system is configured to deliver a virus to an interior of a cell.
16. The particle delivery system of claim 15 , wherein the virus capsid protein and the non-capsid protein are capable of dissociating after delivery into a cell.
17. The particle delivery system of claim 1 , wherein the virus capsid protein is attached to the non-capsid protein by a linker.
18. The particle delivery system of claim 17 , wherein:
the linker comprises amino acids;
the linker is a chemical linker;
the linker is cleavable;
the linker is biodegradable;
the linker comprises (GGGGS) 1-3 , ENLYFQG, or a disulfide; or
each terminus of the non-capsid protein is attached to the virus capsid protein by the linker.
19. The particle delivery system of claim 1 , wherein:
the non-capsid protein is attached to an exterior portion of the virus capsid protein;
the non-capsid protein is attached to an interior portion of the virus capsid protein or is encapsulated within the virus capsid protein;
the virus capsid protein and the non-capsid protein are a fusion protein;
the virus capsid protein and the non-capsid protein are a fusion protein that is attached to a surface of the lipid through an electrostatic interaction;
the non-capsid protein is attached to the virus capsid protein prior to formation of the virus capsid protein; or
the non-capsid protein is attached to the virus capsid protein after formation of the virus capsid protein.
20. The delivery system of claim 4 , wherein the one or more hybrid virus capsid comprise a targeting moiety or a receptor ligand.
21. The particle delivery system of claim 1 , wherein the non-capsid protein comprises a tag or one or more heterologous nuclear localization signals(s) (NLSs).
22. The particle delivery system of claim 9 , wherein the CRISPR protein or peptide is a Type II CRISPR protein or a Type VI CRISPR protein.
23. The particle delivery system of claim 22 , further comprising a guide RNA, optionally complexed with the CRISPR protein.
24. The particle delivery system of claim 22 comprising a protease or nucleic acid molecule(s) encoding a protease that is expressed, whereby the protease cleaves a linker.
25. The delivery system of claim 4 , comprising a first hybrid virus capsid protein and a second hybrid virus capsid protein, wherein the first hybrid virus capsid protein comprises a virus capsid protein attached to a first part of a non-capsid protein, and wherein the second hybrid virus capsid protein comprises a second virus capsid protein attached to a second part of the non-capsid protein, wherein the first part of the non-capsid protein and the second part of the non-capsid protein are capable of associating to form a functional protein.
26. The delivery system of claim 25 , wherein:
the non-capsid protein is a CRISPR protein and the functional protein is a functional CRISPR protein;
the first hybrid virus capsid protein and the second hybrid virus capsid protein form a capsid of a virus particle;
the first hybrid virus capsid protein is located at an interior of a first virus particle and the second hybrid virus capsid protein is located at an interior of a second virus particle;
the first part of the non-capsid protein linked to a first member of a ligand pair, and the second part of the non-capsid protein is linked to a second member of a ligand pair, wherein the first part of the ligand pair is capable of binding to the second part of the ligand pair in a cell,
wherein the first part of the ligand pair inducibly binds to the second part of the ligand pair;
wherein the first part of the non-capsid protein and the second part of the non-capsid protein comprise one or more NLSs; or
wherein the first part or CRISPR protein and the second part of the non-capsid protein or CRISPR protein comprise one or more nuclear export signals (NESs).
27. A particle delivery system comprising a hybrid protein that comprises a virus outer protein attached to at least a portion of a non-virus outer protein,
wherein the hybrid protein is a hybrid virus capsid protein or hybrid viral outer protein coat or hybrid envelope protein, the virus outer protein is a virus capsid or outer protein coat or envelope protein and the non-virus outer protein is a protein that is not a virus outer coat protein, wherein the virus outer protein is adsorbed to a liposome comprising a targeting moiety,
wherein the lipid particle is selected from: EC16-63; 80-O14B; 80-O16B; 80-O18B; 87-O14B; 87-O16B; 87-O18B; 1-O18B; 80-O14; 80-O16; 80-O18; 87-O14; 87-O16; 87-O18; 1-N16; 1-N18; 87-N17; 87-N16; 87-N18; EC16-1; EC16-3; EC-16-12; EC16-14; and mixtures thereof.
28. The particle delivery system of claim 27 , comprising a protease or nucleic acid molecule(s) encoding a protease that is expressed, said protease being capable of cleaving a linker, whereby there can be cleavage of the linker.
29. The particle delivery system of claim 27 , wherein the non-virus outer protein is a CRISPR protein and each terminus of the CRISPR protein is attached to the virus outer protein by a linker.
30. A virus particle comprising one or more hybrid virus capsid protein or one or more hybrid virus outer protein, wherein the one or more hybrid virus capsid proteins comprise a virus capsid protein attached to a non-capsid protein or a CRISPR protein, and the hybrid outer virus protein comprises a virus outer protein attached to a non-virus outer protein or a CRISPR protein, wherein the virus particle is adsorbed to a liposome comprising a targeting moiety,
wherein the lipid particle is selected from: EC16-63; 80-O14B; 80-O16B; 80-O18B; 87-O14B; 87-O16B; 87-O18B; 1-O18B; 80-O14; 80-O16; 80-O18; 87-O14; 87-O16; 87-O18; 1-N16; 1-N18; 87-N17; 87-N16; 87-N18; EC16-1; EC16-3; EC-16-12; EC16-14; and mixtures thereof.
31. A pharmaceutical composition comprising the particle delivery system or the delivery system or the virus particle of claim 1 .